Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America.
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2016
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors sanofi pasteur
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 25 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.